

## DAFTAR PUSTAKA

- Aninomous, 2008, Glucose HK CP, diunduh dari: <http://www.horiba-abx.com>, pada tanggal 3 Februari 2016.
- Altinova AE, Arslan M, Dincel AS, Akturk M, Altan N and Toruner FB, 2007, Uncomplicated Type 1 Diabetes Is Associated with Increased Asymmetric Dimethylarginine Concentrations, *J Clin Endocrinol Metab*, 92(5), p:1881–85.
- Ahmed SS, Laila TR, Nur F, Khan MUI, Mili US, Md. Khan AM, Hoque MR, 2015, Relationship of Glycosylated Hemoglobin with Fasting Plasma Glucose and 2 Hours After Breakfast Plasma Glucose in Type 2 Diabetes, *American Journal of Internal Medicine*, 3(4): 160-164.
- Anderssohn M, Mclachian S, Lunegburg N, Robetrson C, Schwedhelm E, Williamson *et al.*, 2014, Genetic And Environmental Determinants of Dimethylarginines and Association With Cardiovascular Disease in Patients With Type 2 Diabetes, *Care diabetesjournals*, 37: 846-54.
- Anderssohn M, Schwedhelm E, Lunegburg N, Vasan RS, Boger RH, 2010, Asymmetric Dimethylarginine as a Mediator of Vascular Dysfunction and a Marker of Cardiovascular Disease and Mortality: an Intriguing Interaction with Diabetes Mellitus, *Diabetes & Vascular Disease Research*, 7(2), p: 105-18.
- Basak RC, Chatterjee M, Sarma PSA, 2013, An Overview on Management of Diabetic Dyslipidemia, *J. Diabetes Endocrinol*, 4(3), p: 27-36.
- Bayrak T, Bayrak A, Isildak M, Cakir E, Gurlek A, Akbiyik F, 2014, Increased Asymmetric dimethylarginine (ADMA) level and decreased homosisteine thiolactonase/paraaxonase (HTLase/PONase)activities are related to the risk of cardiovascular disease in prediabetic/diabetic patients, *Turkish Journal of Biochemistry-Turk J Biochem*, 39(3): 270-276.
- Bhalerao SD, Somannavar M, Sunil S Vernekar SS, Ravishankar R, And Goudar SS, 2014, Risk Factors For Type 2 Diabetes Mellitus In Rural Population Of North Karnataka: A Community-Based Cross-Sectional Study, *Int. J. Pharm. Med. & Bio. Sc*, p: 1-14.
- Boada CAC and Moreno JMM, 2013, Pathophysiology of Diabetes Mellitus Type 2: Beyond the Duo “Insulin Resistance-Secretion Deficit, *Nutr Hosp*, 28(2): 78-7.
- Beltowski J and Kedra A, 2006, Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy, *Pharmacological Reports*, 58: 159-78.
- BT-Bioassay Technology Laboratory, 2015, ADMA (Asymmetric Dimethylarginine) ELISA, p: 1-15.
- Chatterjee A, Catravas JD, 2008, Endothelial Nitric Oxide (NO) and Its Pathophysiologic Regulation, *Vascular Pharmacology*, 49, p: 134-40.
- Celik M, Cerrah S, Arabul M, Akalin A, 2014, Relation of Asymmetric Dimethylarginine Level to Macrovascular Disease and Inflammation Marker in Type 2 Diabetic Patients, *Journal of Diabetes Research*, p: 1-6.

- Davids M and Teerlink T, 2012, Asymmetric dimethylarginine (ADMA) and cardiovascular disease, *Ned Tijdschr Klin Chem Labgeneesk*, 37 (1):10-14.
- Datta S, Pal M, Mitra R, Ganguly A, Basu S, Manna S, 2014, . Value of assessing post prandial and fasting plasma glucose as a surrogate for glycated hemoglobin in diabetic glycemc control. *World Journal of Pharmaceutical Research*.3(9):494–503.
- Dahlan S, 2004, Statistika Untuk kedokteran dan kesehatan, editor Susalit E, Wangge G, Setiawan H, Arkans, Jakarta, p: 25-40.
- Ekpyong EC, Akpan UP, Ibu JO, Nyebuk DE. 2012, Gender and Age Spesific Prevalence and Associated Risk Faktors of Type 2 Diabetes Mellitus in Uyo Metropolis, *Diabetologia Croatica*, 41(1), p. 17-24.
- Farmer AJ, 2010, Monitoring Diabetes, In: *Textbook of Diabetes*, editor: Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ, 4<sup>th</sup> ed, Wiley Blackwell, p: 399-409
- Ghazanfari Z, Haghdoost AA, Alizadeh SM, Atapour J, Zolala F, 2010, A Comparison of HbA1c and Fasting Blood Sugar Tests in General Population, *Int J Prev Med*, 1(3):187–194.
- Gupta S, Puppalwar PV, Chalak A, 2014, Correlation of fasting and post meal plasma glucose level to increased HbA1c levels in type-2 diabetes mellitus, *Int J Adv Med*.1(2):127-131.
- Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ, 2001, The biology of white adipocyte proliferation, *Obes. Rev.* 2, p: 239–254.
- Hsu CP, Hsu PF, Chung MY, Lin SJ, Lu, TM, 2014, Asymmetric Dimethylarginine And Long-Term Adverse Cardiovascular Events In Patients With Type 2 Diabetes: Relation With The Glycemic Control, *Cardiovascular Diabetology*, 13, p: 1-9.
- Hupfeld CJ, Olefsky Jm, 2016, Type 2 Diabetes Melitus: Etiologi, Pathogenesis, and Natural History, In *Endocrinology: Adult and Pediatric*, 7<sup>th</sup> edition, editor: Jameson JL, De Groot LJ, Kretser D, Guidice LC, Grossman A, Melmed S, Potts JT, Wein GC, p: 691 – 714.
- Hwang JY, Jung CH, Lee MJ, Kang YM, Lee W, Park JY, 2013, Association of Plasma Homocysteine Level and Arterial Stiffness in Subjects with Type 2 Diabetes Mellitus, *J Lipid Atheroscler*; 2(1), p: 27-35
- Idonije BO, Festus O, Oluba O, 2011, Plasma Glucose, Creatinine and Urea Levels in Type 2 Diabetic Patients Attending A Nigerian Teaching Hosital. *Research Journal of Medical Science*, 5 (1), p: 1-3.
- Jawalaker SL, Karnik A, Bhutey A, 2013, Risk of Cardiovascular Diseases in Diabetes Mellitus and Serum Concentration of Asymmetrical Dimethylarginine, *Biochemistry Research International*, p: 1-6.
- Jarniven HY, 2010, Insulin Resistance in Type 2 Diabetes, In: *Textbook of Diabetes*, editor: Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ, 4<sup>th</sup> ed, Wiley Blackwell, p: 174-85.

- Jones PM and Persaud SJ, 2010, Islet Function and Insulin Secretion In: *Textbook of Diabetes*, editor: Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ, 4<sup>th</sup> ed, Wiley Blackwell, p: 87-103.
- Kaku K, 2010, Pathophysiology of Type 2 Diabetes and Its Treatment Policy, *JMAJ*, 53(1): 41-6
- Kaneto H and Matsuoka T, 2012, Involvement of Oxidative Stress in Suppression of Insulin Biosynthesis under Diabetic Conditions, *Int. J. Mol. Sci*, 13, p: 35-46
- Kwon H and Pessin JE, 2013, Adipokines mediate inflammation and insulin resistance, *Frontiers in Endocrinology*, 4 (71), p: 1-13
- Ketema EB and Kibret KT, 2015, Correlation of fasting and postprandial plasma glucose with HbA1c in assessing glycemic control; systemic review and meta-analysis, *Archives of public health*, 73(43), p: 1-9
- Konya H, Miuchi M, Satani K, Matsutani S, Yano Y, Tsunoda T *et al.*, 2015, Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus, *WJEM*, 5(2), p: 110-19.
- Kielstein JT and Zoccali C, 2005, Asymmetric Dimethylarginine: A Cardiovascular Risk Factor and A Uremic Toxin Coming of Age, *Amerikan Journal of Kidney Diseases*, vol. 46, No. 2, p: 186-202.
- Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G, 2007, Asymmetric Dimethylarginine Predict Cardiovascular Events in Patients With Type 2 Diabetes, *Diabetes Care*, 30 (7), p: 1834-1839.
- Lin KY, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM *et al.*, 2002, Impaired Nitric Oxide Synthase Pathway in Diabetes Mellitus, Role of Asymmetric Dimethylarginine and Dimethylarginine Dimethylamino hydrolase, *Circulation*, 106, p: 987-92.
- Lin Y nad Sun Z, 2010, Current views on type 2 diabetes, *Society for Endocrinology*, 201, p: 1-11.
- Liu X, Fassett J, Wei Y, Chen Y, 2013, Review: Regulation of DDAH1 as a Potential Therapeutic Target for Treating Cardiovascular Diseases in: *Evidence-Based Complementary and Alternative Medicine*, Hindawi Publishing corporation, p: 1-6.
- Madenci OC, Yucel N, Arıkan Z, Sargin M, Akbaba D, Kaya O, Kaptanagasi AO, 2013, The Relationship Between Glycemic Control and Asymmetrical Dimethylarginine Levels, *Turk J Biochem*, 38(3), p: 286-90.
- Mahfouz MH, Emara IA, Shouman MS and Ezz MK, 2009, Asymmetrical Dimethylarginine (ADMA) And Nitric Oxide As Potential Cardiovascular Risk Factors In Type 2 Diabetes Mellitus, *Afr. J. Biochem. Res*, 3(8), p: 293-301.
- Masuda Y, Kubo A, Kokaze A, Yoshida M, Fukuhara N, Takashima Y, 2008, Factors Associated With Serum Total Homocysteine Level In Type 2 Diabetes, *Environ Health Prev Med*, 13:148–155.



- Marcovecchio ML, Widmer B, Dunger DB, Dalton RN, 2011, Asymmetric Dimethylarginine in Young People with Type 1 Diabetes: A Paradoxical Association With HbA1c, *Diabet Med*, 28: 685-91.
- Muoio DM and Newgard CB, 2008, Molecular And Metabolic Mechanisms Of Insulin Resistance And B-Cell Failure In Type 2 Diabetes, *Molecular Cell Biology*, 9:193-205.
- Nagamani G, Putcha V, Lind M, and Sridhar GR, 2015, Menstruation in Diabetes Mellitus: A Study from South India, *Journal of Diabetes Research and Therapy*, p. 1-3.
- Nakhjavani M, Jafari K, Esteghamati A, Khalilzadeh O, Asgarani F, Anari AG, 2010, ADMA is a Correlate of Insulin Resistance in Early-Stage Diabetes Independent of hs-CRP and Body Adiposity, *Annales d'Endocrinologie*, 71: p: 303-308.
- Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C *et al.*, 2014, Global, Regional, and National Prevalence of Overweight and Obesity in Children and Adults During 1980-2013: Systematic Analysis for the Global Burden of Disease Study 2013, *Lancet*, 384: 766-81.
- Perkeni, 2011, Perkumpulan Endokrinologi Indonesia, Konsensus Pengendalian dan Pencegahan Diabetes Mellitus Tipe 2 di Indonesia 2011, hh: 4-10.
- Polonsky KS and Burant CF, 2016, Type 2 Diabetes Mellitus, in: *Williams Textbook of Endocrinology*, editor Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, Thirteenth edition, Philadelphia, p: 1385-1450.
- Powers AC, 2012, Diabetes Mellitus, in: *Harrison's Principles of Internal Medicine*, editor : Longo DL, Kasper DL, Jameson JJJ, Fauci AS, Hauser SL, Loscalzo J, 18<sup>th</sup> ed, New York, p: 2968-77.
- RISKESDA, 2013, Badan Penelitian Dan Pengembangan Kesehatan Kementerian Kesehatan RI, hal: 87-92.
- Sacks DB and Path CB, 2006, Carbohydrates in: *Tietz Textbook Clinical Chemistry and Molecular Diagnostics*, edit: Burtis CA, Ashwood ER, Bruns DE, Fourth edition, Philadelphia, p: 868-75.
- Savu O and Tirgoviste CI, 2008, Oxidative Stress Contributions to Chronic Complications In Diabetes, *Proc. Rom Acad*, 3, p: 215-27.
- Schwedhelm E, Xanthakis V, Maas R, Sullivan LM, Schulze F, Riederer U, *et al.*, 2009, Asymmetric Dimethylarginine Reference Intervals Determined with Liquid Chromatography–Tandem Mass Spectrometry: Results from the Framingham Offspring Cohort, *Clinical Chemistry*, 55(8), p: 1539–45.
- Schuzel F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP *et al.*, 2004. Determination of Asymmetric Dimethylarginine (ADMA) using a Novel ELISA Assay, *Clin Chem Lab Med*, 42(12): 1377-38
- Sena CM, Pereira AM, Seica R, 2013, Endothelial Dysfunction- A Major Mediator of Diabetic Vascular Disease, *Biochimica et Biophysica Acta*, 18,32, p: 2216-

- Sibal L, Agarwal SC, Home PD, Boger RH, 2010, The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease, *Current Cardiology*, 6(2), p: 82-90.
- Siervo M, Corander M, Stranges S and Bluck L, 2011, Post-Challenge Hyperglycemia, Nitric Oxide Production and Endothelial Dysfunction: The Putative Role of Asymmetric Dimethylarginine (ADMA), *Nutrition, metabolism & Cardiovascular Diseases*, 21, p: 1-10.
- Skurk T, Alberti-Huber C, Herder C, Hauner H, 2007, Relationship between adipocyte size and adipokine expression and secretion, *J. Clin. Endocrinol. Metab*, 92. p: 1023–1033.
- Soewondo P. 2011, Current Practice in The Management of Type 2 Diabetes in Indonesia : Result from The International Diabetes Management Practices Study (IDMPS), *J. Indon. Med. Assoc*, 61 (12), p: 474-80
- Sukhovshin Ra, Yepuri G, Ghebremariam Yt, 2015, Endothelium-Derived Nitric Oxide As An Antiatherogenic Mechanism: Implications For Therapy”, *MDCVJ* , XI (3), p: 166-71.
- Swetha NK, 2014, Comparison of fasting blood glucose & post prandial blood glucose with HbA1c in assessing the glycemic control, *International J. of Healthcare and Biomedical Research*, Vol 2, (3), p: 134-139.
- Sydow K, Fortmann SP, Fair JM, Varady A, Hlatky MA, Go AS, Iribarren C, et al., 2010, Distribution of Asymmetric Dimethylarginine Among 980 Healthy, Older Adults of Different Ethnicities, *Clinical Chemistry*, 56(1), p: 111-12.
- Takaya J, Tanabe Y, Kuroyanagi Y, and Kaneko K, 2015, Asymmetric dimethylarginine is negatively correlated with hyperglycemia in children, *The Japan Endocrine Society*, p: 1-6
- Tariq K and Khan MA, 2015, Endothelial Dysfunction and Deranged Level of Asymmetric Dimethyl Arginine In Patients with type 2 Diabetes Mellitus, *J Postgrad Med Inst*, 29 (3), p: 143- 50.
- Tayeh O Fahmi A, Islam M, Saied M, 2011, Asymmetric Dimethyl Arginine as a Prognostic Marker For Cardiovascular Complications In Hypertensive Patients , *The Egyptian Heart Journal*, 63, p: 117 – 24.
- Tsikas D, 2008, ” Determination of Asymmetric Dimethylarginine in Biological Fluids: a Paradigm for a Successful analytical Story”, *Curr Opin Nutr Metab Care*, 11, p. 592-600
- Trocha M, Lad AM, Szuba A, Sozanski T, Magdalan J, and Szelag A, 2010, *Asymmetric Dimethylarginine* Synthesis and Degradation Under Physiological and Pathological Conditions, *Adv Clin Exp Med*, 19(2), p: 233-243
- Valliyot B, Sreedharan J, Muttappallymyalil J, Balakrishnan Valliyot Sb, 2013, Risk Factors Of Type 2 Diabetes Mellitus In The Rural Population Of North Kerala, India: A Case Control Study, *Diabetologia Croatica*, 42, p: 33-40.

- Virally M, Blicklé JF, Girard J, Halimi S, Simon D, Guillausseau PJ, 2007, Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives, *Diabetes & Metabolism*, 33, p: 231–244.
- Vlad I and Popa, 2012, Epidemiology of Diabetes Mellitus: A Current Review, *Rom J Diabetes Nutr Metab Dis*, 19(4): 433-44
- Willer AK, Harreiter J, and Giovanni Pacini G, 2016, Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus, *Endocrine Reviews* 37: 278–316.
- Yamagishi S, Ueda S, Okuda S, 2007, Possible Involvement of Crosstalk Between Advanced Glycation End Products (AGEs) and Asymmetric Dimethylarginine (ADMA), an Endogenous Nitric Oxide Synthase Inhibitor In Accelerated Atherosclerosis in Diabetes, *Med Hypotheses*; 69, p: 922-4.

